| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| cf102 | adenosine a3 receptor | NA | Clinical trial target | TTD , DGIDB | Hepatitis C[MeSHID:D006526] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Liver carcinoma[MeSHID:D006528] |
NA | phase 2 | unknown |
| cf102 | adenosine a3 receptor | NA | Clinical trial target | TTD , DGIDB | Hepatitis C[MeSHID:D006526] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Liver carcinoma[MeSHID:D006528] |
1.91 | phase 2 | agonist |
| cf102 | adenosine a3 receptor | NA | Clinical trial target | TTD , DGIDB | Hepatitis C[MeSHID:D006526] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Liver carcinoma[MeSHID:D006528] |
1.91 | phase 2 | unknown |
| click here to return to the previous page | ||||||||